SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 33.92 |
| Enterprise Value ($M) | 53.64 |
| Book Value ($M) | 22.15 |
| Book Value / Share | 0.13 |
| Price / Book | 1.53 |
| NCAV ($M) | -12.12 |
| NCAV / Share | -0.07 |
| Price / NCAV | -2.80 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.37 |
| Return on Assets (ROA) | -0.33 |
| Return on Equity (ROE) | -36.15 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.33 |
| Current Ratio | 3.41 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 112.17 |
| Assets | 146.45 |
| Liabilities | 124.30 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 2.56 |
| Operating Income | -141.40 |
| Net Income | -37.45 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -130.90 |
| Cash from Investing | 66.99 |
| Cash from Financing | 20.29 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 4.80 | -2.84 | |
| 13G | BlackRock, Inc. | 6.70 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 214,486 | 745,342 | 28.78 | |
| 540,660 | 1,464,158 | 36.93 | |
| 519,720 | 1,292,396 | 40.21 | |
| 409,970 | 1,275,755 | 32.14 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| WINT – Windtree Therapeutics, Inc. | XBIO – Xenetic Biosciences, Inc. |
| XCUR – Exicure, Inc. | ZURA – Zura Bio Limited |
Financial data and stock pages provided by
Fintel.io